03/12/2020
Participants
Objectives of the Workpackage
The primary goal of WP 5 is to develop genomic and metabolomic based prediction of psychoses, that has been contended by similarly performing, neurocognitive and clinical prediction models, as recently shown by our consortium. Recent observations suggest that the information needed for a reliable single-subject prediction of psychoses is not solely confined to neuroimaging data but is rather distributed across different data dimensions and modalities. Possibly, these distributed information profiles constitute multi-modal signatures of psychoses-related risk. Thus, it is likely that genetic and metabolomic markers within multi-modal prognostic surrogate marker set will give complimentary sources of information and may provide even higher levels of diagnostic certainty.
Description of the tasks
WP 5 is led by the 
University of Munich LMU and is responsible to ensure sample collection, sample preparation, sample storage, sample transport and sample banking according to standardised protocol with quality control.
GWAS analysis and selection of predictor SNPs and candidate metabolites of related pathways will be performed. Furthermore, analyses of the SNPs of the selected predictor genes and selected candidate metabolites to identify and cross-validate multivariate genetic and metabolic biomarker signatures for clinical endpoint prediction.
Partners
Institute of Human Genetics (Direktor: Prof. Thomas Meitinger) Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg.
Scientific Collaboration
Dr. Mu Mint, Department of Psychiatry, LMU Munich
